Chahal H, D'Souza S W, Barson A J, Slater P
School of Biological Sciences, University of Manchester.
Arch Dis Child Fetal Neonatal Ed. 1998 Mar;78(2):F116-20. doi: 10.1136/fn.78.2.f116.
To investigate age related alterations in glutamate N-methyl-D-aspartate (NMDA) receptor binding produced by the modulatory compounds glutamate, glycine, and magnesium (Mg2+) sulphate.
The effects produced by glutamate plus glycine, and Mg2+ on the binding of [3H]MK-801, a ligand for the N-methyl-D-aspartate ion channel phencyclidine site, were measured in membrane preparations made from prefrontal cortex from human neonate (n = 5), infant (n = 6), and adult (n = 6) necropsy brains.
Neonatal brains had the least [3H]MK-801 binding, suggesting either a low density of NMDA receptors or a more restricted access of [3H]MK-801 to cation channel sites. Infant brains had the most [3H]MK-801 binding which was stimulated to a greater extent by L-glutamate (100 microM) and glycine (10 microM) than in neonatal and adult brains. MG2+ invariably inhibited [3H]MK-801 binding. However, the Mg2+ IC50 value was higher in neonatal brain (3.6 mM) than infant (1.4 mM) and adult (0.87 mM) brains.
Infant brain may have excess NMDA receptors which are hyper responsive to glutamate and glycine. The lower potency of Mg2+ to inhibit [3H]MK-801 binding in neonatal cortex may be because newborn babies have NMDA receptors without the normal complement of Mg2+ sites. The findings suggest that therapeutic NMDA receptor block in neonates requires higher concentrations of magnesium sulphate in brain tissue.
研究调节性化合物谷氨酸、甘氨酸和硫酸镁对谷氨酸N-甲基-D-天冬氨酸(NMDA)受体结合产生的年龄相关性改变。
在取自人类新生儿(n = 5)、婴儿(n = 6)和成人(n = 6)尸检脑前额叶皮质的膜制剂中,测定谷氨酸加甘氨酸以及镁离子对N-甲基-D-天冬氨酸离子通道苯环己哌啶位点配体[3H]MK-801结合的影响。
新生儿脑的[3H]MK-801结合最少,提示NMDA受体密度低或[3H]MK-801进入阳离子通道位点的机会更受限。婴儿脑的[3H]MK-801结合最多,L-谷氨酸(100微摩尔)和甘氨酸(10微摩尔)对其刺激程度大于新生儿脑和成人脑。镁离子始终抑制[3H]MK-801结合。然而,新生儿脑的镁离子半数抑制浓度(IC50)值(3.6毫摩尔)高于婴儿脑(1.4毫摩尔)和成人脑(0.87毫摩尔)。
婴儿脑可能有过量的NMDA受体,这些受体对谷氨酸和甘氨酸反应过度。镁离子在新生儿皮质中抑制[3H]MK-801结合的效力较低,可能是因为新生儿的NMDA受体缺乏正常的镁离子位点补充。研究结果表明,新生儿治疗性NMDA受体阻断需要脑组织中更高浓度的硫酸镁。